News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|June 19, 2024

Complement System Role in PNH Treatment Approach

Dr Haumschild continues leading a discussion surrounding management of PNH, emphasizing the impact of complement inhibitors.

Episodes in this series

EP. 1 PNH Overview and Pathophysiology

EP. 1 PNH Overview and Pathophysiology

EP. 2 Intravascular and Extravascular Hemolysis MoA in PNH

EP. 2 Intravascular and Extravascular Hemolysis MoA in PNH

EP. 3 Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming

EP. 3 Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming

EP. 4 Key Treatment Considerations for Patients Diagnosed With PNH

EP. 4 Key Treatment Considerations for Patients Diagnosed With PNH

EP. 5 Complement System Role in PNH Treatment Approach

EP. 5 Complement System Role in PNH Treatment Approach

EP. 6 Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

EP. 6 Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

EP. 7 Efficacy End Points For PNH Treatment

EP. 7 Efficacy End Points For PNH Treatment

EP. 8 Efficacy and Safety Trials Results of Complement Inhibitors

EP. 8 Efficacy and Safety Trials Results of Complement Inhibitors

EP. 9 Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration

EP. 9 Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration

EP. 10 Investigational Therapies Paving New PNH Treatment Pathways

EP. 10 Investigational Therapies Paving New PNH Treatment Pathways

EP. 11 Key Financial Factors Associated With Typical PNH Treatment Journey

EP. 11 Key Financial Factors Associated With Typical PNH Treatment Journey

EP. 12 Navigating Transfusion Requirements in PNH Treatment

EP. 12 Navigating Transfusion Requirements in PNH Treatment

EP. 13 Considerations for Managing PNH Treatment Complications

EP. 13 Considerations for Managing PNH Treatment Complications

EP. 14 Infection Risk Management Counseling For Patients Receiving Treatment for PNH

EP. 14 Infection Risk Management Counseling For Patients Receiving Treatment for PNH

A panel of 4 experts on PNH

EP. 15 Ensuring PNH Treatment Access and Adherence to Therapies

A panel of 4 experts on PNH

EP. 16 Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Video content above is prompted by the following:

How does an understanding of the complement system’s role in paroxysmal nocturnal hemoglobinuria inform therapeutic approaches or interventions for patients with this condition?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Richard Lafayette, MD | Image Credit: Stanford Medicine

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

ByBrooke McCormick,Richard Lafayette, MD, FACP

August 3rd 2026

Longer-Acting DME Drugs Ease Burden, Not Vision: John Kitchens, MD

ByLaura Joszt, MA,John Kitchens, MD

August 3rd 2026

Brittany Craiglow, MD in part 1 of an AJMC Q&A

The Psychiatric Burden of Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD

BySkylar Jeremias,Brittany G. Craiglow, MD, FAAD

August 3rd 2026

Man clutching his stomach. | Image credit: @Shisuka_AdobeStock.jpeg

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

BySabrina McCrear

July 31st 2026

Peptide vial | Image credit: Iurii - stock.adobe.com

FDA Panel Backs 6 Peptides for Compounding

ByPearl Steinzor

July 31st 2026

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps